Discover
BHVN
Biohaven Ltd.
14.75
1 x 14.72
8 x 14.74
bid
ask
-
0.76
4.90%
2 @ 04:50 PM
14.99 +0.24 (1.63%)
| Ytd | 30.65% | |
| 1y | 9.83% |
14.56
day range
15.50
7.48
52 week range
18.57
| Open | 15.26 | Prev Close | 15.51 | Low | 14.56 | High | 15.50 | Mkt Cap | 1.61B |
| Vol | 2.17M | Avg Vol | 2.88M | EPS | -5.67 | P/E | -2.68 | Forward P/E | -7.97 |
| Beta | 3.14 | Short Ratio | 5.15 | Inst. Own | 91.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 12.55 | 200-d Avg | 11.65 | 1yr Est | 21.94 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.77 | N/A | N/A | N/A |
| 2026-05-04 | 2026-03 | -0.86 | -0.88 | -0.02 | -2.33% |
| 2026-03-02 | 2025-12 | -1.22 | -1.21 | 0.01 | 0.82% |
| 2025-11-10 | 2025-09 | -1.91 | -1.64 | 0.27 | 14.14% |
| 2025-08-11 | 2025-06 | -1.94 | -1.94 | N/A | N/A |
| 2025-05-12 | 2025-03 | -1.67 | -2.17 | -0.5 | -29.94% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-29 | B of A Securities | Downgrade | Neutral | Underperform |
| 2026-05-26 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2026-05-13 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-05 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-04-02 | Citigroup | Upgrade | Buy | Buy |
| 2026-03-11 | TD Cowen | Upgrade | Buy | Buy |
Profile
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-11-12 | BAILEY GREGORY HUGH | Director | 2.02M | Purchase |
| 2026-01-04 | BUTEN MATTHEW | Chief Financial Officer | 195.65K | Conversion of Exercise of derivative security |
| 2026-01-04 | CAR BRUCE | Officer | 37.72K | Conversion of Exercise of derivative security |
| 2025-11-12 | CHILDS JOHN W | Director | 0.00 | Purchase |
| 2026-01-04 | CLARK GEORGE C. | Officer | 86.98K | Conversion of Exercise of derivative security |
| 2026-01-04 | CORIC VLADIMIR | Chief Executive Officer | 3.85M | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Janus Henderson Group PLC | 17.53M | 272.66M | 11.65% |
| 2026-03-30 | Blackrock Inc. | 11.22M | 174.51M | 7.45% |
| 2026-03-30 | Suvretta Capital Management, LLC | 10.29M | 159.96M | 6.83% |
| 2026-03-30 | Stifel Financial Corporation | 9.94M | 154.58M | 6.60% |
| 2026-03-30 | State Street Corporation | 6.62M | 102.92M | 4.40% |
| 2026-03-30 | Infinitum Asset Management, LLC | 6.25M | 97.19M | 4.15% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.26M | 66.18M | 2.83% |
| 2026-05-30 | iShares Trust-iShares Russell 2000 ETF | 2.80M | 43.48M | 1.86% |
| 2026-03-30 | JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 2.22M | 34.52M | 1.47% |
| 2026-03-30 | JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 1.77M | 27.45M | 1.17% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.45M | 22.53M | 0.96% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.27M | 19.74M | 0.84% |